Omeros begins dosing in second Phase II study of OMS824 in Huntington's Disease

US-based clinical-stage biopharmaceutical firm Omeros has dosed the first patient in a second Phase II clinical trial of its phosphodiesterase 10 (PDE10) inhibitor OMS824, being developed for the treatment of schizophrenia, Huntington's disease (HD) …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news